NO20061417L - Syreinneholdende oxaliplatinformuleringer - Google Patents

Syreinneholdende oxaliplatinformuleringer

Info

Publication number
NO20061417L
NO20061417L NO20061417A NO20061417A NO20061417L NO 20061417 L NO20061417 L NO 20061417L NO 20061417 A NO20061417 A NO 20061417A NO 20061417 A NO20061417 A NO 20061417A NO 20061417 L NO20061417 L NO 20061417L
Authority
NO
Norway
Prior art keywords
acid
formulation
containing oxaliplatin
oxaliplatin
oxaliplatin formulations
Prior art date
Application number
NO20061417A
Other languages
English (en)
Inventor
Vanstone Darryl Whittaker
Julie Aikun Liu
Original Assignee
Mayne Pharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2003904627A external-priority patent/AU2003904627A0/en
Application filed by Mayne Pharma Pty Ltd filed Critical Mayne Pharma Pty Ltd
Publication of NO20061417L publication Critical patent/NO20061417L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Det tilveiebringes en farmasøytisk flytende formulering av oxaliplatin for parenteral administtasjon, nevnte formulering omfattende (i) oxaliplatin; (ii) vann og (iii) en syre hvori syren er stabiliserende og ikke er malonsyre, melkesyre eller oksalsyre. Fremgangsmåter for å fremstille formuleringen er også beskrevet. Det tilveiebringes ytterhgere anvendelsen av formuleringen i fremstillingen av et medikament for behandlingen av cancer og en fremgangsmåte for å behandle cancer som omfatter å administtere en terapeutisk mengde av en farmasøytisk formulering.
NO20061417A 2003-08-28 2006-03-28 Syreinneholdende oxaliplatinformuleringer NO20061417L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2003904627A AU2003904627A0 (en) 2003-08-28 Pharmaceutical Formulation
PCT/AU2004/001168 WO2005020980A1 (en) 2003-08-28 2004-08-27 Acid containing oxaliplatin formulations

Publications (1)

Publication Number Publication Date
NO20061417L true NO20061417L (no) 2006-03-28

Family

ID=34230045

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061417A NO20061417L (no) 2003-08-28 2006-03-28 Syreinneholdende oxaliplatinformuleringer

Country Status (10)

Country Link
US (5) US20050090544A1 (no)
EP (2) EP1680103A4 (no)
JP (4) JP2007504098A (no)
CN (3) CN102048723A (no)
CA (1) CA2537170A1 (no)
DE (1) DE112004001563T5 (no)
GB (1) GB2421911A (no)
NO (1) NO20061417L (no)
NZ (1) NZ545591A (no)
WO (1) WO2005020980A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2388352A1 (en) * 2002-05-31 2003-11-30 Voiceage Corporation A method and device for frequency-selective pitch enhancement of synthesized speed
CA2537170A1 (en) * 2003-08-28 2005-03-10 Mayne Pharma Pty Ltd Acid containing oxaliplatin formulations
DE102004052877B4 (de) * 2004-11-02 2008-06-19 Ebewe Pharma Ges.M.B.H. Nfg.Kg Stabile wässrige Formulierungen eines Platin-Derivats
DE102005038347A1 (de) * 2005-08-11 2007-02-15 Hexal Ag Herstellung einer Oxaliplatin-Lösung und Behälter sowie Behälter-Set mit der Lösung
WO2007029268A2 (en) 2005-09-05 2007-03-15 Dabur Pharma Limited Stable oxaliplatin formulation
KR100913063B1 (ko) 2006-09-13 2009-08-21 주식회사유한양행 옥살리플라틴-함유 주사용 용액
US20100267824A1 (en) * 2007-11-12 2010-10-21 Intas Pharmaceuticals Limited Stable oxaliplatin composition for parenteral administration
CN101461801B (zh) * 2008-12-26 2013-05-15 辰欣药业股份有限公司 一种奥沙利铂药物组合物及其制备方法
MX348668B (es) 2009-09-21 2017-06-23 J W Pharmaceutical Corp * Nanopartículas de oxaliplatin y método para prepararlas.
JP5929607B2 (ja) * 2012-08-06 2016-06-08 ニプロ株式会社 オキサリプラチン製剤
WO2014174102A1 (en) * 2013-04-26 2014-10-30 Sanofi Tartrate salt of 5-chloro-thiophene-2-carboxylic acid [(s)-2-[methyl-3-(2-oxo-pyrrolidin-1-yl)-benzenesulfonylamino]-3-(4-methyl piperazin-1 -yl)-3-oxo-propryl]amide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US19514A (en) * 1858-03-02 Improvement in seeding-machines
AU2989695A (en) 1994-08-08 2000-03-07 Debiopharm S.A. Pharmaceutically stable oxaliplatinum preparation
AU2163797A (en) * 1996-03-11 1997-10-01 Debiopharm S.A. Binuclear platinum complexes, method for preparing same and pharmaceutical compositions containing said complexes
GB9804013D0 (en) * 1998-02-25 1998-04-22 Sanofi Sa Formulations
CA2382389C (fr) * 1999-08-30 2010-06-29 Debiopharm S.A. Preparation pharmaceutique stable d'oxaliplatine pour administration par voie parenterale
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
DE10314377A1 (de) * 2003-03-28 2004-10-07 Stada Arzneimittel Ag Gebrauchsfertige Oxaliplatin-Lösungen
CA2537170A1 (en) * 2003-08-28 2005-03-10 Mayne Pharma Pty Ltd Acid containing oxaliplatin formulations
US20060063833A1 (en) * 2004-09-22 2006-03-23 Edgar Schridde Ready-to-use oxaliplatin solutions

Also Published As

Publication number Publication date
EP2243480A1 (en) 2010-10-27
JP2008201804A (ja) 2008-09-04
EP1680103A4 (en) 2009-03-25
JP2015180699A (ja) 2015-10-15
HK1111894A1 (zh) 2008-08-22
US20070155833A1 (en) 2007-07-05
NZ545591A (en) 2008-11-28
WO2005020980A1 (en) 2005-03-10
JP6078593B2 (ja) 2017-02-08
GB2421911A (en) 2006-07-12
GB0606187D0 (en) 2006-05-10
CA2537170A1 (en) 2005-03-10
EP1680103A1 (en) 2006-07-19
US20100035982A1 (en) 2010-02-11
DE112004001563T5 (de) 2006-07-27
CN102048723A (zh) 2011-05-11
JP2007504098A (ja) 2007-03-01
CN101022790A (zh) 2007-08-22
JP2012072191A (ja) 2012-04-12
US20100063145A1 (en) 2010-03-11
CN101703467A (zh) 2010-05-12
JP2014080426A (ja) 2014-05-08
US20060264501A1 (en) 2006-11-23
US20050090544A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
RU2356547C2 (ru) Способы лечения рака с использованием ингибиторов hdac
WO2003079979A3 (en) Method for treating congestive heart failure
GEP20063895B (en) Platinum derivative pharmaceutical formulations
NO20050204L (no) Kombinasjoner av legemidler for behandling av neoplasmer
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
NO20060307L (no) Anvendelse av kinoazolinderivatet ZD6474 kombinert med platinaforbindelser og eventuelt ioniserende straling i behandling av sykdommer assosoiert med angiogenese og/eller okt vaskulaert permeabilitet
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
UA86977C2 (ru) Производные гидантоина для лечения обструктивных болезней дыхательных путей
MX2023005533A (es) Derivado de triazina diona, metodo de preparacion y aplicacion del mismo en medicina.
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
EE200200565A (et) Vaskulaarse kahjustava toimega kombinatsioonravi
WO2008045378A3 (en) Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin
WO2004006849A3 (en) Combinations of drugs for the treatment of neoplasms
IS8187A (is) Meðferð á fráhvarfseinkennum
MXPA05008583A (es) Terapia de combinacion de zd6474 con 5-fu y/o cpt-11.
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
NO20063277L (no) Farmasoytisk sammensetning av vinflunin som er ment for parenteral administrering, fremstillingsmate og anvendelse derav
GB2421911A (en) Acid containing oxaliplatin formulations
IS8186A (is) Meðferð fyrir uppskurð á verkjum eftir uppskurð
ATE421882T1 (de) Schnellösliches azithromycin in einzeldosisform
TW418100B (en) Device for transdermal and phonophoretic combination treatment and its therapeutic uses
BRPI0508982A (pt) uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
WO2004043486A8 (en) An acqueous pharmaceutical formulation comprising the thrombin inhibitor melagatran and use of the formulation in the manufacture of a medicament for use by nasal administration in treating thromboembolism

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application